APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80

STI-201CN2

SERIAL NO.

09/632,056

Clifford A. Lingwood et al

LIST OF PUBLICATIONS CITED BY APPLICANT

several sheets innecessary)

August 3, 2000

1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
lub	A1	5,801,145	09/98	Gariepy	514	12	
1/4							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
							

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)						
21	A2	Farkas-Himsley, et al: "Bacterial Proteinaceous Products (Bacteriocins) as Cytotoxic Agents of						
场。		Neoplasia", Cancer Research, vol. 36, pp. 3562-3567 (Oct. 1976).						
()"	А3	Hill, et al: "Further studies of the Action of a Partially Purified Bacteriocin against a Murine						
\mathcal{I}		Fibrosarcoma", Cancer Research, vol. 51, pp. 1359-1365 (March 1, 1991)						
	A4	Karmali: "Infection by Verocytotoxin-Producing Escherichia coli", Clinical Microbiology Reviews,						
		vol. 2, no. 1, pp. 15-38 (Jan. 1989)						
	A5	Riley, et al: "Hemorrhagic Colitis Associated with a Rare Escherichia Coli Serotype", The New						
		England Journal of Medicine, vol. 308, no. 12, pp. 681-685 (March 24, 1983)						
	A6	Lingwood: "Verotoxin and Their Glycolipid Receptors", Advances in Lipid Research, vol. 25, pp.						
		189-211 (1993)						
	A7	van de Kar, et al: "Tumor Necrosis Factor and Interleukin-1 Induce Expression of the						
		Verocytotoxin Receptor Globotriaosylceramide on Human Endothelial Cells: Implications						
	A8	Obrig, et al: "Endothelial Heterogeneity in Shiga Toxin Receptors and Responses", The Journal						
	,	of Biological Chemistry, vol. 268, no. 21, pp. 15484-15488 (July 25, 1993)						
	A9	Lingwood: "Verotoxin-Binding in Human Renal Sections", Nephron, vol. 66, pp. 21-28 (1994)						
	A10	Cohen, et al: "Expression of Glycolipid Receptors to Shiga-like Toxin on Human B Lymphocytes:						
	i i	a Mechanism for the failure of long-lived antibody response to dysenteric disease", <i>International</i>						
		Immunology, vol. 2, no. 1, pp. 1-8 (1990)						
	A11	Gregory, et al: "Identification of a Subset of Normal B Cells with a Burkitt's Lymphoma (BL)-Like						
		Phenotype", <i>The Journal of Immunology</i> , vol. 139, no. 1, pp. 313-318 (July 1, 1987)						
	A12	Maloney, et al: "CD19 has a Potential CD77 (Globotriaosyl Ceramide)-binding Site with						
		Sequence Similiarity to Verotoxin B-subunits: Implications of Molecular Mimicry for B Cell						
		Adhesion and Enterohemorrhagic Escherichia Coli Pathogenesis", J. Exp. Med., vol. 180, pp.						
		191-201 (July 1994)						
	A13	Maloney, et al: "Interaction of Verotoxins with Glycosphingolipids", <i>Trends in Glycoscience and</i>						
1 1	1	Glycotechnology, vol. 5, no. 21, pp. 23-31 (January 1993)						
	A14	Li, et al: "Accumulation of Globotriaosylceramide in a case of Leiomyosarcoma", Biochemistry						
		J., vol. 240, pp. 925-927 (1986)						
	A15	Mannori, et al: "Role of Glycolipids in the Metastatic Process: Characteristics of Neutral						
1		Glycolipids in Clones with Different Metastatic Potentials Isolated from a Murine Fibrosarcoma						
1	A16	Ohyama, et al: "Changes in Glycolipid Expression in Human Testicular Tumor", Intl. J. Cancer,						
4		vol. 45, pp. 1040-1044 (1990)						
Examine	r o	Date Considered/						
//	. 1/							

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT	FACSIMILE	OF	FORM	PTO-	1449



ATTY DOCKET NO.
STI-201CN2

APPLICANT

, |

09/632,056

(Use several sheets if necessary)

DEC 2 0 2000 C

Clifford A. Lingwood et al.

August 3, 2000

1633

W. 26 M

THERS (Micluding Author, Title, Date, Pertinent Pages, Etc.) Naiki, et al: "Human Erythrocyte P and Pk Blood Group Antigens: Identification as Glycosphingolipids", Biochemical and Biophysical Research Communications, vol. 60, no. 3, pp. 1105-1111 (1974) B2 Pallesen, et al: "Distribution of the Burkitt's Lymphoma-associated Antigen (BLA) in Normal Human Tissue and Malignant Lymphoma as Defined by Immunohistological Staining with Monoclonal Antibody 38.13", J. Cancer Res. Clin. Oncol., vol. 113, pp. 67-86 (1987) Kasai, et al: "Tissue Distribution of the Pk Antigen as Determined by a Monoclonal Antibody", Journal of Immunogenetics, vol. 12, pp. 213-220 (1985) Pudymaitis, et al: "Susceptibility to Verotoxin as a Function of the Cell Cycle", Journal of Cellular Physiology, vol. 150, pp. 632-639 (1992) **B**5 Lingwood, et al: "Glycolipid Modification of α2 Interferon Binding", Biochem, J., vol. 283, pp. 25-26 (1992) В6 Sandvig, et al: "Retrograde Transport of Endocytosed Shiga Toxin to the Endoplasmic Reticulum", Nature, vol. 358, pp. 510-512 (August 6, 1992) В7 Mangeney, et al: "Apoptosis induced in Burkitt's lymphoma cells via Gb₃/CD77, a glycolipid antigen", Cancer Res., vol. 53, pp. 5314-5319 (1993) Costello, et al. "Human cerebral endothelium; Isolation and characterization of cell derived from microvessels of non-neoplastic and malignant glial tissue" J. Neuro Oncol., vol. 8, pp. 231-243 (1990)В9 Pintus, et al. "Endothelial cell growth supplement: a cell cloning factor that promotes the growth of mono-clonal antibody producing hydridoma cells", J. Immunological Methods, vol. 61, pp. 195-200 (1983) Rutka, et al. "Characterization of normal human brain cultures: Evidence for the outgrowth of leptomeningeal cells", Laboratory Investigation; vol. 55, pp. 71-85 (1986) B11 Sandvig et al. "Toxin Induced Cell Lysis: Protection by 3-Methyladenine and Cycloheximide" EXP CELL, vol. 200, pp. 253-262 (1992). Head, et al.: "Purification and characterization of verocytotoxin 2", FEMS Microbiology Letters, 51, pp. 211-216 (1988) Ramotar, et al. "Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron", *Biochem. J.*, vol. 272, pp. 805-811 (1990) Buzask Date Considered Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

Igitial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line throug citation if not in conformance and not considered. Include copy of this form with next communication to applicant.